0001209191-21-029907.txt : 20210504
0001209191-21-029907.hdr.sgml : 20210504
20210504163530
ACCESSION NUMBER: 0001209191-21-029907
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210430
FILED AS OF DATE: 20210504
DATE AS OF CHANGE: 20210504
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Priti
CENTRAL INDEX KEY: 0001859997
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36327
FILM NUMBER: 21889109
MAIL ADDRESS:
STREET 1: C/O NEOLEUKIN THERAPEUTICS, INC.
STREET 2: 188 EAST BLAINE STREET, #450
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Neoleukin Therapeutics, Inc.
CENTRAL INDEX KEY: 0001404644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-732-2133
MAIL ADDRESS:
STREET 1: SUITE 360 - 1616 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC
DATE OF NAME CHANGE: 20140128
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC
DATE OF NAME CHANGE: 20070626
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-30
0
0001404644
Neoleukin Therapeutics, Inc.
NLTX
0001859997
Patel Priti
C/O NEOLEUKIN THERAPEUTICS, INC.
188 EAST BLAINE STREET, #450
SEATTLE
WA
98102
0
1
0
0
Chief Medical Officer
Restricted Stock Units
0.00
2021-04-30
4
A
0
20000
0.00
A
Common Stock
20000
20000
D
Stock Option (Right to Buy)
12.49
2021-04-30
4
A
0
475000
0.00
A
2031-04-30
Common Stock
475000
475000
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of April 30, 2022 and April 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.
The option vests as to 1/4 of the total shares on April 30, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Kris McGrew, as Attorney-in-Fact for Priti Patel
2021-05-04